ArticleHaematologica2020
Abstract readLetter
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.Leukemia · 2026Article
- Epigenetic alterations in Myeloid Malignancies.Advances in experimental medicine and biology · 2026Review
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.Leukemia · 2025Review
- Review
- Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature.BJC reports · 2025Article
- Epigenetic dysregulation in acute myeloid leukemia.Seminars in hematology · 2025Review
- GMP-like and MLP-like Subpopulations of Hematopoietic Stem and Progenitor Cells Harboring MutatedInternational journal of molecular sciences · 2025Article
- Article
- Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.Cancers · 2024Review
- The epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer.Stem cells (Dayton, Ohio) · 2024Review
- Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics.International journal of molecular sciences · 2024Review
- Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation.Haematologica · 2023Article
- Article
- UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.Blood cancer journal · 2023Article
- Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.International journal of molecular sciences · 2023Review
- The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia.International journal of molecular sciences · 2023Review
- Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.PloS one · 2023Article
- Acute myeloid leukemia: novel mutations and their clinical implications.American journal of blood research · 2023Review
- Understanding blood development and leukemia using sequencing-based technologies and human cell systems.Frontiers in molecular biosciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Sebastian StasikUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Jan M MiddekeUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Michael KramerUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Christoph RölligUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Alwin KrämerUniversitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.
Sebastian SchollUniversitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany.
Andreas HochhausUniversitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany.
Martina CrysandtUniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostasiologie und Stammzelltransplantation, Aachen, Germany.
Tim H BrümmendorfUniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostasiologie und Stammzelltransplantation, Aachen, Germany.
Ralph NaumannSt. Marien-Krankenhaus Siegen, Medizinische Klinik III, Siegen, Germany.
Björn SteffenUniversitätsklinikum Frankfurt, Medizinische Klinik II, Frankfurt am Main, Germany.
Volker KunzmannUniversitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
Hermann EinseleUniversitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
Markus SchaichRems-Murr-Klinikum Winnenden, Klinik für Hämatologie, Onkologie und Palliativmedizin, Winnenden, Germany.
Andreas BurchertPhilipps Universität Marburg, Klinik für Hämatologie, Onkologie, Immunologie, Marburg, Germany.
Andreas NeubauerPhilipps Universität Marburg, Klinik für Hämatologie, Onkologie, Immunologie, Marburg, Germany.
Kerstin Schäfer-EckartKlinikum Nürnberg Nord, Klinik für Innere Medizin V, Nürnberg, Germany.
Christoph SchliemannUniversitätsklinikum Münster, Medizinische Klinik A, Münster, Germany.
Stefan KrauseUniversitätsklinikum Erlangen, Medizinische Klinik V, Erlangen, Germany.
Regina HerbstKlinikum Chemnitz, Medizinische Klinik III, Chemnitz, Germany.
Mathias HänelKlinikum Chemnitz, Medizinische Klinik III, Chemnitz, Germany.
Norbert FrickhofenHSK Wiesbaden, Innere Medizin III, Wiesbaden, Germany.
Richard NoppeneyUniversitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany.
Ulrich KaiserSt. Bernward Krankenhaus, Medizinische Klinik II, Hildesheim, Germany.
Claudia D BaldusCharité-Universitätsmedizin Berlin, Hämatologie und Onkologie, Berlin, Germany.
Martin KaufmannRobert-Bosch-Krankenhaus, Abteilung für Hämatologie, Onkologie und Palliativmedizin, Stuttgart, Germany.
Zdenek RácilMasaryk University and University Hospital, Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic.
Uwe PlatzbeckerUniversitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I, Hämatologie und Zelltherapie, Leipzig, Germany.
Wolfgang E BerdelUniversitätsklinikum Münster, Medizinische Klinik A, Münster, Germany.
Jiri MayerMasaryk University and University Hospital, Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic.
Hubert ServeUniversitätsklinikum Frankfurt, Medizinische Klinik II, Frankfurt am Main, Germany.
Carsten Müller-TidowUniversitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.
Gerhard EhningerUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Martin BornhäuserUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Johannes ScheteligUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany.
Christian ThiedeUniversitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany christian.thiede@uniklinikum-dresden.de.
Study Alliance Leukemia (SAL)
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteEnhancer of Zeste Homolog 2 ProteinHumansMutationEnhancer of Zeste Homolog 2 ProteinEZH2 protein, human
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.